Indivior signs deal to sell schizophrenia drug in Canada

HLS Therapeutics

09/05/2019 12:12

May 9 (Reuters) - British drugmaker Indivior Plc  INDV.L  on
Thursday signed a licensing agreement with HLS Therapeutics Inc
 HLS.TO  for the sale of its schizophrenia drug Perseris in
Canada.
    Perseris, launched in the United States in February, is
approved by the FDA for the treatment of schizophrenia in
adults. The drug delivers its active ingredient, risperidone, in
an extended-release delivery system with no loading doses or
oral supplementation recommended.  urn:newsml:reuters.com:*:nRSa2980Ra
    Indivior has been looking to reduce its dependence on its
best-selling Suboxone film, after the opioid addiction treatment
was hit by steep market share losses to generic rivals. 
    Indivior, which gets most of its revenue from Suboxone in
the United States, was indicted last month for illegal marketing
of Suboxone in the U.S. and was fined $3 billion.  urn:newsml:reuters.com:*:nL3N21S1VL

 (Reporting by Justin George Varghese in Bengaluru; Editing by
James Emmanuel)
 ((justin.varghese@thomsonreuters.com; Tel: +91 80 6749 3486;
Reuters Messaging:
justin.varghese.thomsonreuters.com@reuters.net))